Patents by Inventor James Matthaei

James Matthaei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USE FOR CAR T CELLS
    Publication number: 20240075069
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 7, 2024
    Inventors: Philip Stewart LOW, Haiyan CHU, Yingjuan June LU, Christopher Paul LEAMON, Leroy W. WHEELER, II, Michael C. JENSEN, James MATTHAEI
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20240010703
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: August 22, 2023
    Publication date: January 11, 2024
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee VAN DER VUURST DE VRIES, Joshua BEILKE, Vivianne MALMSTRÖM, Kathryn HOOPER, Rebecca JOHNSON, Lars KLARESKOG
  • PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
    Publication number: 20230322925
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Application
    Filed: March 24, 2023
    Publication date: October 12, 2023
    Inventors: Michael C. Jensen, James Matthaei
  • Methods of use for CAR T cells
    Patent number: 11779602
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: October 10, 2023
    Assignees: Endocyte, Inc., Purdue Research Foundation, Seattle Children's Hospital
    Inventors: Philip Stewart Low, Haiyan Chu, Yingjuan June Lu, Christopher Paul Leamon, Leroy W. Wheeler, II, Michael C. Jensen, James Matthaei
  • Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory T cells to treat autoimmune diseases
    Patent number: 11753457
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: September 12, 2023
    Assignees: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James Matthaei, Anne-Renee van der Vuurst de Vries, Joshua Beilke, Vivianne Malmström, Kathryn Hooper, Rebecca Johnson, Lars Klareskog
  • Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
    Patent number: 11649288
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 16, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, James Matthaei
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20230080155
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 16, 2023
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee Van Der Vuurst De Vries, Joshua Beilke, Vivianne Malmstrom, Kathryn Hooper, Rebecca Johnson, Lars Klareskog
  • METHODS OF USE FOR CAR T CELLS
    Publication number: 20220257652
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: January 27, 2022
    Publication date: August 18, 2022
    Inventors: Michael C. Jensen, James Matthaei
  • SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR AN ANTI-FLUORESCEIN CAR T CELLS AND FLUORESCEIN-PHOSPHOLIPID-ETHERS OR PROFLUORESCEIN-PHOSPHOLIPID-ETHERS
    Publication number: 20220125841
    Abstract: Some embodiments of the methods and compositions provided herein relate to modulating signaling of anti-hapten CAR T cells, such as anti-fluorescein CAR T cells, by the use or administration of an unconjugated hapten, such as unconjugated fluorescein or a salt or derivative thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: April 28, 2022
    Inventors: Michael C. Jensen, James Matthaei
  • Methods of use for CAR T cells
    Patent number: 11311576
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: April 26, 2022
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, James Matthaei
  • SEQUENCING METHOD FOR CAR T CELL THERAPY
    Publication number: 20210346431
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: February 22, 2019
    Publication date: November 11, 2021
    Inventors: Richard MESSMANN, Christopher Paul LEAMON, Haiyan CHU, Yingjuan June LU, Philip Stewart LOW, Michael C. JENSEN, James MATTHAEI, Navin Robert Charles PINTO, Julie Ruggieri PARK
  • CELL BASED METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME
    Publication number: 20200405881
    Abstract: Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.
    Type: Application
    Filed: March 6, 2018
    Publication date: December 31, 2020
    Applicants: UNIVERSITY OF WASHINGTON, SEATTLE CHILDREN'S RESEARCH INSTITUTE, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Patrick S. STAYTON, Anthony CONVERTINE, Debobrato DAS, Hye-Nam SON, Selvi SRINIVASAN, Katherine MONTGOMERY, Ian BLUMENTHAL, Courtney CRANE, Michael JENSEN, James MATTHAEI, John CHIEFARI, Maarten DANIAL, Fei HUANG, James MACDONALD, Almar POSTMA, Kathleen TURNER
  • PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
    Publication number: 20200087399
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Application
    Filed: February 6, 2018
    Publication date: March 19, 2020
    Inventors: Michael C. Jensen, James Matthaei
  • METHODS OF USE FOR CAR T CELLS
    Publication number: 20190255109
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: January 22, 2019
    Publication date: August 22, 2019
    Inventors: Philip Stewart LOW, Haiyan CHU, Yingjuan June LU, Christopher Paul LEAMON, Leroy W. WHEELER, II, Michael C. JENSEN, James MATTHAEI
  • METHODS OF USE FOR CAR T CELLS
    Publication number: 20190224237
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Inventors: Michael C. Jensen, James Matthaei